ACHIEVE LIFE SCIENCES, INC.
ACHVNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ACHV. That does not mean none is planned.
Get an email about ACHV's next catalysts
Track ACHIEVE LIFE SCIENCES (ACHV) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 2 past
QUIT Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.20 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
Cytisinicline
Smoking Cessation
custirsen sodium
Non-small Cell Lung Cancer
Custirsen
Prostate Cancer
cabazitaxel
Prostate Cancer
TOCOSOL(R) Paclitaxel
Breast Cancer
OGX-427
Castration Resistant Prostate Cancer
custirsen (OGX-011)/docetaxel
Prostate Cancer
TOCOSOL Paclitaxel
Bladder Neoplasms
Experimental Arm: TOCOSOL Paclitaxel
Urologic Neoplasms
S-8184 Paclitaxel Injectable Emulsion
Urologic Neoplasms
custirsen (OGX-011)/mitoxantrone
Prostate Cancer
Cytisine
Smoking Cessation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cytisinicline | Phase 3 | Smoking Cessation | - | - |
custirsen sodium | Phase 3 | Non-small Cell Lung Cancer | - | - |
Custirsen | Phase 3 | Prostate Cancer | - | - |
cabazitaxel | Phase 3 | Prostate Cancer | - | - |
TOCOSOL(R) Paclitaxel | Phase 2 | Breast Cancer | - | - |
OGX-427 | Phase 2 | Castration Resistant Prostate Cancer | - | - |
custirsen (OGX-011)/docetaxel | Phase 2 | Prostate Cancer | - | - |
TOCOSOL Paclitaxel | Phase 2 | Bladder Neoplasms | - | - |
Experimental Arm: TOCOSOL Paclitaxel | Phase 2 | Urologic Neoplasms | - | - |
S-8184 Paclitaxel Injectable Emulsion | Phase 2 | Urologic Neoplasms | - | - |
custirsen (OGX-011)/mitoxantrone | Phase 2 | Prostate Cancer | - | - |
Cytisine | Phase 2 | Smoking Cessation | - | - |
Frequently asked questions
What is in ACHIEVE LIFE SCIENCES, INC.'s drug pipeline?β
CatalystAlert tracks 12 drug candidates in ACHIEVE LIFE SCIENCES, INC.'s (ACHV) pipeline across Phase 3, Phase 2. Its lead program is cabazitaxel (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ACHIEVE LIFE SCIENCES, INC.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for ACHIEVE LIFE SCIENCES, INC. (ACHV) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track ACHV biotech catalysts?β
Add ACHV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ACHIEVE LIFE SCIENCES, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
